# US 2016/0250256 A1 · Tumoricidal and antimicrobial compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250256 A1
- Document ID: US20160250256A1
- Status: Published application
- Kind: A1
- Application number: 15/032,518
- Filed: 2014-10-28
- Published: 2016-09-01
- Earliest claimed: 2013-11-01
- Assignees: NantKwest, Inc.
- Applicants: NantKwest, Inc.
- Inventors: Hans G. Klingemann; Barry J. Simon
- Web page: https://patentgrep.com/patent/US20160250256A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 38/2013: {IL-2}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/44: Fungal antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- Y02A 40/70: in livestock or poultry
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

## Claims

### Claim 1

A composition comprising isolated exosomes and/or microvesicles from NK-92 cells.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition comprises a sterile aqueous solution.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the sterile aqueous solution comprises one or more pharmaceutically acceptable excipients.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the the sterile aqueous solution comprises sterile PBS or sterile saline solution.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the sterile aqueous composition comprises a supernatant of a medium of NK-92 cells.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the exosomes and/or microvesicles are isolated from a defined subpopulation of NK-92 cells.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the NK-92 cells are treated with at least one stimulatory agent prior to isolation of the exosomes and/or microvesicles.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the at least one stimulatory agent is IL-15 and/or interferon gamma.

### Claim 9

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more isolated components from NK-92 cells, wherein the one or more components are tumoricidal and/or anti-microbial.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the composition comprises a sterile aqueous solution.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the sterile aqueous solution comprises a supernatant of a medium of NK-92 cells.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9, wherein the one or more components comprise exosomes and/or microvesicles.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1 and a sterile aqueous carrier.

### Claim 14 (depends on 9)

The pharmaceutical composition of claim 9, wherein the NK-92 cells comprise wild type NK-92 cells.

### Claim 15 (depends on 9)

The pharmaceutical composition of claim 9, wherein the NK-92 cells comprise modified NK-92 cells.

### Claim 16 (depends on 9)

The pharmaceutical composition of claim 9, wherein the NK-92 cells comprise NK-92 cells modified to express an Fc receptor, a cytokine, a cytokine receptor and/or a chimeric antigen receptor.

### Claim 17 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is an injectable formulation.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the pharmaceutical composition is formulated for subdermal or subcutaneous injection.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the pharmaceutical composition is an injectable extended release formulation.

### Claim 20 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical acceptable carrier comprises a thickening agent.

### Claim 21 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is a topical formulation.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the topical formulation is liquid at room temperature and becomes a gel when applied to the body.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein the topical formulation comprises a poloxamer.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the pharmaceutical composition is a cream or lotion.

### Claim 25 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises one or more cytokines.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the one or more cytokines includes at least IL-2.

### Claim 27 (depends on 9)

The pharmaceutical composition of claim 9, wherein the NK-92 cells are treated with at least one stimulatory agent prior to isolation of the one or more components.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the at least one stimulatory agent is IL-15 and/or interferon gamma.

### Claim 29 (depends on 9)

A method for treating a tumor in a patient comprising administering an effective amount of the pharmaceutical composition of claim 9 to the patient so as to treat the tumor.

### Claim 30 (depends on 9)

A method for treating an infection in a patient, said method comprising comprising administering an effective amount of the pharmaceutical composition of claim 9 to the patient so as to treat the infection.

### Claim 31 (depends on 30)

The method of claim 30, wherein the infection is a bacterial infection, a viral infection, a fungal infection, or a yeast infection.

### Claim 32 (depends on 9)

A method for inducing an immune response in a patient, said method comprising comprising administering an effective amount of the pharmaceutical composition of claim 9 to the patient so as to induce an immune response.

### Claim 33 (depends on 9)

A method for inducing an immunomodulatory response in a patient, said method comprising injecting a patient with an effective amount of the pharmaceutical composition of claim 9 so as to induce an immunomodulatory response.

### Claim 34

A kit comprising a first pharmaceutical composition comprising a pharmaceutically acceptable carrier and isolated exosomes and/or microvesicles from NK-92 cells, and a second pharmaceutical composition comprising a gel, wherein the first pharmaceutical composition and the second pharmaceutical composition are topical formulations.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the second pharmaceutical composition comprises a poloxamer.

### Claim 36 (depends on 34)

The kit of claim 34, wherein the second pharmaceutical composition comprises exosomes and/or microvesicles isolated from the supernatant of a growth medium of NK-92 cells.
